BackgroundCheck.run
Search For

Glenn R Pierce, 642534 Royal Palm Way, Fort Lauderdale, FL 33327

Known as:
Glenn Living Pierce Glenn B Pierce
Related to:
Dorothy Wason Wason Katy R Gallagher 53 Heather Malin 61

Glenn Pierce Phones & Addresses

2534 Royal Palm Way, Weston, FL 33327    954-6590579    954-9995743   

Wichita, KS   

29 Whitebarn Ln, Norwell, MA 02061    781-6597136    781-6597140   

Burbank, CA   

Philadelphia, PA   

Wayne, PA   

New York, NY   

Get Report
Control this profile

Mentions for Glenn R Pierce

Career records & work history

Medicine Doctors

Glenn Pierce Photo 1

Glenn Francis Pierce

Specialties:
Internal Medicine
Infectious Disease
Pathology
Education:
Case Western Reserve University(1984)

Glenn Pierce resumes & CV records

Resumes

Glenn Pierce Photo 48

Glenn Pierce

Location:
United States
Glenn Pierce Photo 49

Glenn Pierce

Location:
United States
Glenn Pierce Photo 50

Professional

Location:
United States

Publications & IP owners

Us Patents

Factor Ix Polypeptides And Methods Of Use Thereof

US Patent:
2013020, Aug 8, 2013
Filed:
Jul 11, 2011
Appl. No.:
13/809276
Inventors:
Glenn Pierce - Cambridge MA, US
Samantha Truex - Sudbury MA, US
Robert T. Peters - West Roxbury MA, US
Haiyan Jiang - Belmont MA, US
Assignee:
Biogen Idec Hemophilia Inc. - Waltham MA
International Classification:
A61K 38/48
A61K 39/395
US Classification:
4241341, 424 9464, 435188, 43525233, 536 232
Abstract:
The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Methods Of Reducing Immunogenicity Against Factor Viii In Individuals Undergoing Factor Viii Therapy

US Patent:
2023000, Jan 5, 2023
Filed:
Feb 25, 2022
Appl. No.:
17/681435
Inventors:
- Waltham MA, US
- Seattle WA, US
Sriram KRISHNAMOORTHY - Medford MA, US
Neil JOSEPHSON - Seattle WA, US
Glenn PIERCE - Cambridge MA, US
International Classification:
C12Q 1/6883
A61K 38/21
A61K 39/00
A61K 38/37
C07K 14/755
A61K 47/68
Abstract:
The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Assays To Monitor Bleeding Disorders

US Patent:
2020038, Dec 10, 2020
Filed:
Apr 14, 2020
Appl. No.:
16/848445
Inventors:
- Waltham MA, US
Haiyan JIANG - Belmont MA, US
Xin ZHANG - Weston MA, US
Buyue YANG - Arlington MA, US
Glenn PIERCE - Rancho Santa Fe CA, US
International Classification:
G01N 33/86
C12N 9/64
Abstract:
The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.

Methods Of Reducing Immunogenicity Against Factor Viii In Individuals Undergoing Factor Viii Therapy

US Patent:
2019024, Aug 8, 2019
Filed:
Jan 11, 2019
Appl. No.:
16/246225
Inventors:
- Waltham MA, US
- Seattle WA, US
Sriram Krishnamoorthy - Medford MA, US
Neil Josephson - Seattle WA, US
Glenn Pierce - Cambridge MA, US
International Classification:
C12Q 1/6883
C07K 14/755
A61K 47/68
A61K 39/00
A61K 38/21
A61K 38/37
Abstract:
The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Methods Of Reducing Immunogenicity Against Factor Viii In Individuals Undergoing Factor Viii Therapy

US Patent:
2014037, Dec 18, 2014
Filed:
Jan 12, 2013
Appl. No.:
14/371931
Inventors:
- Cambridge MA, US
- Seattle WA, US
Sriram Krishnamoorthy - Medford MA, US
Neil Josephson - Seattle WA, US
Glenn Pierce - Cambridge MA, US
International Classification:
A61K 47/48
C12Q 1/68
A61K 38/37
US Classification:
4241781
Abstract:
The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Isbn (Books And Publications)

Executions In America

Author:
Glenn L. Pierce
ISBN #:
0669856703

Legal Homicide: Death As Punishment In America, 1864-1982

Author:
Glenn L. Pierce
ISBN #:
0930350251

Growth Factors And Wound Healing: Basic Science And Potential Clinical Applications

Author:
Glenn F. Pierce
ISBN #:
0387949682

Manzoni And The Aesthetics Of The Lombard Seicento: Art Assimilated Into The Narrative Of I Promessi Sposi

Author:
Glenn Palen Pierce
ISBN #:
0838753671

Possible Relatives

Cynthia A Pierce  David J Pierce  Cyrus R Pierce  Davis J Pierce  Dawn M Pierce  Dean Pierce  Deana J Pierce  Glenn Johnson  Glenn M Stanchfield  Glenn A Stanford 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.